SCHEMBL4182433

SCHEMBL4182433

CCCn1c(=O)c2c(nc(Cc3ccc(CCO)cc3)n2CCNCC)n(CCc2ccccc2N)c1=O

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ADORA1 P30542 2/20 0.41
ADORA2B P29275 7/20 0.41
ADORA2A P29274 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
ADORA3 P0DMS8 1/20 0.37
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176276 0.93 ADORA2B (0.43) TSHRADORA1ADORA2BADORA2AKMT2A
SCHEMBL4171247 0.92 ADORA2B (0.47) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL4175968 0.89 ADORA1 (0.51) TSHRADORA1ADORA2BADORA2AL3MBTL1
SCHEMBL1333406 0.87 ADORA2B (0.45) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL4173722 0.86 ADORA1 (0.46) TSHRADORA1ADORA2BADORA2AL3MBTL1
SCHEMBL1334723 0.86 ADORA2B (0.45) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL4171267 0.85 ADORA2B (0.49) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL1334339 0.85 ADORA2B (0.48) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL4182614 0.85 ADORA2B (0.44) TSHRADORA1ADORA2BADORA2AADORA3
SCHEMBL4182298 0.84 ADORA2B (0.39) TSHRADORA1ADORA2BADORA2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US claimed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US claimed
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US disclosed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US disclosed
EP-1636230-A2 A1 ADENOSINE RECEPTOR ANTAGONISTS Endacea, Inc. (US) 2006-03-22 EP disclosed
WO-2004110379-A2 A1 ADENOSINE RECEPTOR ANTAGONISTS ENDACEA, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility HRH3, HRH1, HRH2 TSHR 1275/4885ADORA1 4/4885ADORA2B 9/4885
US-20090068101-A9 A1 Adenosine Receptor Antagonists ADORA1, ADORA3, ADORA2A TSHR 197/4885ADORA1 1/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.